NanoSyrinx, a synthetic biology company focused on developing nanosyringes for targeted intracellular delivery of biologic therapeutics, has successfully closed a financing round worth approximately £10 million ($13 million). This investment will accelerate the development of the company's technology platform, allowing it to target previously "undruggable" intracellular sites with biologic therapeutics. The company also revealed the appointment of Dr. Edwin Moses as Chairman of its Board of Directors.

The financing round was co-led by BGF, Octopus Ventures, and M Ventures, with participation from new corporate investor Eli Lilly and Company, alongside existing investors IQ Capital and Meltwind. The fresh capital will be used to advance NanoSyrinx’s platform, which utilizes naturally occurring “nanosyringes” to selectively deliver peptide and protein-based therapeutics, such as gene editors and enzymes, directly into the cytosol of specific cells.

In addition to the financing, Dr. Edwin Moses has taken over as Chairman, replacing Stephen Taylor, who has been with the company since its inception. Dr. Moses brings more than three decades of experience in the life sciences sector, having held board positions at over 20 companies. His notable achievements include leading biotech companies like Ablynx NV, which Sanofi acquired for $4.8 billion, and Oxford Asymmetry International, sold to Evotec for £316 million. He also guided both companies through successful IPOs. His leadership is expected to help NanoSyrinx maximize the potential of its nanosyringe platform through a combination of internal pipeline development and strategic partnerships.

“Edwin has significant experience as a successful CEO and Chairman, with extensive involvement in biotech fundraising, strategic commercial partnerships, and successful exits. We are thrilled to have him joining as Chair of our Board as we drive forward with our ambitious plans. He joins us at a pivotal stage alongside this financing, which places us in a well-capitalized position to further develop our intracellular drug delivery technology to realize its full potential in developing medicines. We would like to thank Steve for all his help over the years and recognize the instrumental part he has played in getting the company to where it is today,” said Dr. Joe Healey, CEO of NanoSyrinx

Dr. Edwin Moses, the new Chairman, commented: “NanoSyrinx’s technology promises to make a tremendous positive difference to the very challenging problem of intracellular delivery of therapeutics. I am delighted to join the Board and help build on the momentum of this latest fundraise, to support the company and its leadership team in the further development of this unique platform which has the potential to create enormous value and make a real difference to patients’ lives.”

Lucy Edwardes Jones, an investor at BGF, also expressed her enthusiasm.“While huge advances have been made in the field of biologic therapies, the delivery challenge remains a key bottleneck. We are excited by the potential of NanoSyrinx’s unique technology to unlock this, enabling promising new drugs to reach previously inaccessible disease targets in the body. We are looking forward to working closely with Edwin, the team, and our co-investors to see this exciting technology through to impact.”